PMA paints grim picture of country's healthcare
As per the "Health of the Nation Report 2025", with an estimated population of over 253 million, growing at an alarming rate of 2.4% annually, the country is projected to reach 403 million by 2050. This demographic surge threatens food security, healthcare access, education, and housing. Yet, policymakers have failed to develop sustainable strategies to address these challenges. The report lists a myriad of challenges, from soaring maternal and child mortality rates to the ongoing threat of preventable diseases, demanding urgent reforms at every level. Pakistan ranks 125th out of 170 countries in terms of healthcare, according to the World Health Organisation's (WHO) rankings for December 2024.
Dr Abdul Ghafoor Shoro said polio cases surged to 74 in 2024 from just six in 2023.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Recorder
6 days ago
- Business Recorder
Challenge of cancer treatment, prevention
EDITORIAL: Recently, Pakistan has launched two significant public health partnership initiatives aimed at tackling cancer prevention and treatment. First, just a few days ago, the Federal Ministry of Health signed an agreement with the World Health Organisation (WHO) to participate in the Global Platform for Access to Child Cancer. This programme is designed to improve the availability and accessibility of lifesaving treatments for children battling cancer. With approximately 8,000 children diagnosed each year, this collaboration is expected to make a profound difference in the lives of young patients and their families. In addition, the Gates Foundation has announced plans to begin rolling out cervical cancer vaccinations next month. According to a senior official from the Foundation's Gender Equity Division, the initial phase will target girls aged 9 to 11, with the eventual goal of extending the vaccine to older girls and women. Access to both cancer treatment and prevention remains a critical challenge in many parts of the world, particularly in developing countries like Pakistan, where the cost of treatment can be prohibitively high for most families. In many low- and middle-income countries, the lack of affordable healthcare is one of the leading reasons behind the significantly lower cancer survival rates. In Pakistan, for instance, the current survival rate for children with cancer stands at just 30 percent, far below the 80 percent survival rate found in high-income countries. However, the federal Ministry of Health has expressed hope that by 2030, the survival rate for children in Pakistan could rise to 60 percent. That though is possible only if access to quality treatment becomes more widespread and affordable. Our participation in the Global Platform for Access to Child Cancer represents a vital opportunity for thousands of families who would otherwise be unable to afford such treatments. While providing free medicines is an essential step, it's equally crucial to raise public awareness about these resources. Effective communication is needed so that families in need can fully benefit from the available support. Turning to the second initiative, the HPV vaccine has already been successfully introduced in 25 African countries with the support of Gavi, the Vaccine Alliance — a public-private global health partnership. This initiative has saved millions of lives by preventing cervical cancer, a disease that disproportionately affects women in low- and middle-income countries. Undoubtedly, the HPV vaccine is one of the most effective methods for reducing cervical cancer incidence; it should be integrated into Pakistan's national vaccination programme, focusing initially on girls and young women. The success of HPV vaccination, along with the provision of quality-assured, free medicines — procured and distributed by UNICEF — could dramatically increase the survival rate of children diagnosed with cancer. The successful implementation of similar initiatives in other parts of the world highlights the potential impact of collaborative efforts between governments, international organisations, and health initiatives to combat preventable diseases. By replicating these programmes, Pakistan could make significant progress in cancer prevention and treatment, saving thousands of lives. Copyright Business Recorder, 2025
Business Recorder
08-08-2025
- Business Recorder
Better access to childhood cancer treatment
EDITORIAL: Pakistan has recently signed an agreement with the World Health Organisation (WHO) to participate in the Global Platform for Access to Childhood Cancer, an initiative designed to enhance the availability and accessibility of life-saving treatments for children battling cancer. With approximately 8,000 children diagnosed annually, this agreement is expected to have a significant impact on the lives of young patients and their families. At the signing event, WHO Representative in Pakistan, Dr Dapeng Luo, emphasised the importance of the collaboration with the Ministry of Health and other partners, including UNICEF — which will be responsible for the procurement and distribution of medicines — adding that 'no child is to be left behind, no matter where they live or who they are.' One of the most encouraging aspects of this agreement is the provision of quality-assured, free medicines, which could greatly increase the survival rate of children diagnosed with cancer. Access to cancer treatment, particularly for paediatric patients, remains a critical challenge in many parts of the world, especially in developing countries like Pakistan, where the cost of treatment can be prohibitively high for most families. In many countries, the lack of affordable healthcare is one of the primary reasons behind significantly lower cancer survival rates. In Pakistan, for instance, the current survival rate for children with cancer, as per official figures, stands at 30 percent, far below the 80 percent survival rate in high-income countries. The federal health ministry has expressed the hope that by 2030 the survival rate for children in Pakistan could increase to 60 percent. That is possible only if access to quality treatment becomes more widespread and affordable. Our participation in the Global Platform represents a vital opportunity for thousands of families who would otherwise be unable to afford cancer treatment. However, along with the provision of free medicines, it is essential to raise public awareness about the availability of these resources. The new initiative must be effectively communicated so that families in need can take full advantage of its support. There are other successful public health initiatives that Pakistan can learn from. In Africa, for example, 25 countries have introduced the HPV vaccine for cervical cancer prevention with the support of Gavi, the Vaccine Alliance — a public-private global health partnership. It has saved millions of lives by preventing cervical cancer, a disease that disproportionately affects women in low- and- middle-income countries. HPV vaccination has proven to be one of the most effective ways for reducing the incidence of cervical cancer. Pakistan should also seriously consider integrating the HPV vaccine into its national vaccination programme, focusing on girls and young women. The success of the HPV vaccination initiative in Africa serves as a powerful example of what can be achieved when governments, international organisations, and health initiatives work together to tackle preventable diseases. By replicating such programmes, Pakistan can make significant strides in cancer prevention and treatment, potentially saving thousands of lives. Copyright Business Recorder, 2025
Express Tribune
08-08-2025
- Express Tribune
Cabinet exempts import of unregistered drugs
Listen to article The government has approved exemption for the import of certain unregistered drugs, which will be used in hospitals and institutions. The National Health Services, Regulation and Coordination (NHSR&C) Division apprised the cabinet in a recent meeting that the Drug Regulatory Authority of Pakistan (DRAP) was mandated to regulate the manufacturing, import, export, distribution and sale of therapeutic goods as well as enforce the Drugs Act, 1976. The division shared that access to unapproved therapies for patients was a global phenomenon and drug regulators around the world provided special mechanisms for such access under certain conditions to ensure the availability of lifesaving drugs. It was highlighted that the World Health Organisation's Global Benchmarking Tool for regulatory practices also included mechanisms to provide access to unapproved therapeutic products in the interest of public health. The NHSR&C Division apprised the forum that Section 36 of the Drugs Act stipulated that the federal government may, if it is of the opinion that the public interest so requires, at any time, of its own motion or on a representation made to it, by notification in the official gazette, exempt any drug or class of drugs from the operation of any of the provisions of this Act, subject to such conditions, if any, and for such period, as may be specified in the notification. The division said that the import of any drug that was not registered or was not in accordance with the conditions of registration was prohibited under Section 23(1)(a)(vii) of the Drugs Act. However, exemption was granted to hospitals and institutions for the import of anti-cancer drugs, cardiac drugs and any essential lifesaving drugs, as considered by the licensing authority, under certain conditions prescribed in SRO 134(1)/2021 dated February 24, 2021. The exemption was given to provide access to innovative therapies that were yet to be registered under the Drugs Act. The five-year exemption expired on January 21, 2025. The NHSR&C Division told the cabinet that DRAP, in its 198th meeting held on January 27, 2025, recommended a five-year extension in the exemption period, starting from January 22, 2025, for anti-cancer drugs, cardiac drugs and any essential lifesaving drugs, as considered by the licensing authority. These drugs were to be imported for use in hospitals and institutions under Section 23(1)(a)(ii) of the Drugs Act, subject to following conditions: Imports shall be made with prior approval of the licensing authority under Rule 9 of the Drugs (Import and Export) Rules, 1976. The drug shall not be sold or distributed in the market. It shall be on free sale in the country of origin except for lifesaving vaccines and anti-sera for human use only, where pre-qualification by the World Health Organisation (WHO) or approval from any regulatory authority, as defined by the registration board, is provided. The drug shall be used for therapeutic purposes in hospitals or institutions only, and not for the purpose of clinical trials, examination, testing or analysis. A clearance certificate must be obtained from the assistant director concerned at the time of arrival of the shipment, before Customs' clearance. Consumption or utilisation record must be maintained by the importer, under the supervision of a qualified person. The drug is not registered or available in Pakistan, provided that the condition mentioned in Serial No (c) shall not apply to medicines and vaccines used in the treatment and prevention of Covid-19. A draft notification, vetted by the Ministry of Law and Justice, was also placed before the cabinet for consideration. During discussion, cabinet members inquired about the rationale for the proposed exemption, responding to which the NHSR&C Division explained that the import or local production of such essential lifesaving medicines was not commercially viable as the number of patients requiring those medicines was limited. Therefore, hospitals and institutions were constrained to import them. The cabinet considered a summary titled "Exemption for Import of Certain Unregistered Drugs for Use in Hospitals and Institutions" and approved the proposals.
